University of Galway launch of NO-CANCER-NET

Read more

Triple Negative Breast Cancer (TNBC) affects about 10-15% of women diagnosed with breast cancer. It is highly aggressive and challenging to treat as it lacks hormone receptors, making targeted therapies ineffective. Treatment options for TNBC are limited to surgery and chemotherapy.

NO-CANCER-NET (Advanced Engineering of Nitric Oxide Based Therapeutics for Triple Negative Breast Cancer Training Network) is a 4-year, €2.7million Horizon Europe MSCA Doctoral Network Grant award from the European Research Executive Agency to address unmet medical need for TNBC.

The network is led by Professor Sharon Glynn, Fulbright Scholar and Professor in Pathology at University of Galway in collaboration with CÚRAM.

The network will train 10 doctoral candidates across 6 European countries and 9 institutions, focussing on three areas centred on expanding nitric oxide (NO) based therapeutics for the treatment of TNBC

  1. Investigating the role of NOS in the development and progression of TNBC. 
  2. Developing a lab model to identify the best therapeutic approaches and test novel drugs.  
  3. Synthesising new drugs that target NO tumour biology and testing if they work best alone or in combination with existing therapies. 

Doctoral Candidate Training Centres

  • University of Galway (Ireland)
  • Trinity College Dublin (Ireland)
  • University of Udine (Italy)
  • University of Siena (Italy)
  • National Research Council of Italy
  • EPHE PSL Research University Paris (France)
  • University of Seville (Spain)
  • University of Luxembourg 
  • Danish Cancer Institute (Denmark) 

Associated Partners

  • Galway University Hospital (Ireland)
  • Galway Clinic (Ireland)
  • Houston Methodist Hospital, National Institutes of Health (USA)
  • 3DBioFibr (Canada)
  • InProTher (Denmark)
  • Catalyze (Netherlands)
  • University of Bologna (Italy)
  • Innovamol Consulting (Italy)